Guest: Andrew Cutler, MD

In the third and final chapter of this series for the “Keep the Body in Mind” initiative, Dr. Cutler discusses strategies that could improve care for patients with bipolar disorder or schizophrenia and talks about recommendations for evaluating and monitoring health conditions.

This is an informational non-CME program sponsored by Alkermes, Inc. ALKERMES® is a registered trademark of Alkermes, Inc. KEEP THE BODY IN MIND® is a registered service mark of Alkermes Pharma Ireland Limited, used by Alkermes, Inc., under license. ©2020 Alkermes, Inc. All rights reserved.

None of the subjects pictured are actual patients.

UNB-002975

Host: Jennifer Caudle, DO

Guest: Tracey Evans, MD

Join Dr. Tracey Evans as she discusses the efficacy data for TAGRISSO® (osimertinib) and the potential impact for metastatic EGFRm NSCLC patients.

In 2018, first-line TAGRISSO became a standard of care for metastatic EGFRm NSCLC with an unprecedented 18.9 months median PFS vs 10.2 months for erlotinib/gefitinib (HR=0.46 [95% CI: 0.37, 0.57]; P<0.0001).1

Now, TAGRISSO is the only EGFR TKI to deliver statistically significant Overall Survival beyond 3 years in a global, phase 3 randomized clinical trial in the first-line setting, (38.6 months vs 31.8 months for erlotinib/gefitinib (HR=0.799 [95.05% CI: 0.641, 0.997]; P=0.0462)).2

Visit TagrissoHCP.com to learn what these data could mean for your patients.

FLAURA study design: Randomized, double-blind, active-controlled trial in 556 patients with metastatic EGFRm NSCLC who had not received prior systemic treatment for advanced disease. Patients were randomized 1:1 to either TAGRISSO (n=279; 80 mg orally, once daily) or EGFR-TKI comparator (n=277; gefitinib 250 mg or erlotinib 150 mg orally, once daily). All US patients in the comparator arm received erlotinib. Crossover was allowed for patients in the EGFR-TKI comparator arm at confirmed progression if positive for the EGFR T790M resistance mutation. Patients with CNS metastases not requiring …

Host: Jennifer Caudle, DO

Guest: Tracey Evans, MD

Join Dr. Tracey Evans as she discusses the efficacy data for TAGRISSO® (osimertinib) and the potential impact for metastatic EGFRm NSCLC patients.

In 2018, first-line TAGRISSO became a standard of care for metastatic EGFRm NSCLC with an unprecedented 18.9 months median PFS vs 10.2 months for erlotinib/gefitinib (HR=0.46 [95% CI: 0.37, 0.57]; P<0.0001).1

Now, TAGRISSO is the only EGFR TKI to deliver statistically significant Overall Survival beyond 3 years in a global, phase 3 randomized clinical trial in the first-line setting, (38.6 months vs 31.8 months for erlotinib/gefitinib (HR=0.799 [95.05% CI: 0.641, 0.997]; P=0.0462)).2

Visit TagrissoHCP.com to learn what these data could mean for your patients.

FLAURA study design: Randomized, double-blind, active-controlled trial in 556 patients with metastatic EGFRm NSCLC who had not received prior systemic treatment for advanced disease. Patients were randomized 1:1 to either TAGRISSO (n=279; 80 mg orally, once daily) or EGFR-TKI comparator (n=277; gefitinib 250 mg or erlotinib 150 mg orally, once daily). All US patients in the comparator arm received erlotinib. Crossover was allowed for patients in the EGFR-TKI comparator arm at confirmed progression if positive for the EGFR T790M resistance mutation. Patients with CNS metastases not requiring ...

Host: Jennifer Caudle, DO

Guest: Peter McAllister, MD

While both small molecule drugs and monoclonal antibodies are considered targeted therapies, they each have unique characteristics that may influence how they’re used to treat diseases. That’s why Dr. Peter McAllister is here to explain how these two modalities differ in terms of structure, administration routes, and distribution.

USA-334-83595

Host: Matt Birnholz, MD

Guest: Joel Weinthal, MD

Type 1 Gaucher disease is a progressive and lifelong genetic disease, and when the diagnosis is missed, this can lead to some serious implications or consequences. And since hematologists-oncologists play a pivotal role in identifying and diagnosing these patients, Dr. Matt Birnholz speaks with Dr. Joel Weinthal, Medical Director at Medical City Hospital, about the symptoms of Gaucher disease hematologists-oncologists should look for, how to test and diagnose, the consequences of diagnostic delays, and more.

MAT-US-2003112 5/2020

Guest: Juan Ochoa, MD

Join Dr. Juan Ochoa, Medical Director of Surgical Intensive Care at Oschsner Medical Center, as he reviews a retrospective study that investigated the impacts of high-protein, low-calorie feedings on critically ill patients in the ICU. Dr. Ochoa is a Surgeon, physician scientist, and former Chief Medical Officer of Nestlé Health Science.

Guest: Mark Ryan, PharmD

The more time that passes before a snake bite is treated, the higher the risk of long-term or even permanent morbidity due to tissue damage. So when time is tissue, why risk it?

Join Dr. Mark Ryan from the Louisiana Poison Control Center as he shares important information on the antivenom CroFab®, including its development, how it quickly controls envenomation effects, and its demonstrated safety profile.

Guest: Spencer Greene, MD, MS, FACEP, FACMT, FAAEM

The Unified Treatment Algorithm is a consensus guideline prepared by a panel of experts that provides a simple, step-by-step guide on assessing and treating a patient who’s been bitten by a pit viper. Knowing the correct treatment approach is just as important as understanding what not to do, as Dr. Spencer Greene explains.

Guest: William Banner, MD, PhD

Tissue damage caused by North American pit viper envenomation occurs quickly in snake bite victims. Join Dr. Bill Banner as he discusses three critical aspects of snake bite management and how treatment with CroFab® can be a viable option for patients.

Host: Jennifer Caudle, DO

Guest: Riley Bove, MD

Guest: Bianca Weinstock-Guttman, MD

The disease course of multiple sclerosis (MS) can take many paths based on numerous factors, including age at diagnosis, gender, and MS subtype. Layered upon the typical MS management challenges are those that can occur with the physical and physiological changes of the normal aging process. How might the care of a patient with MS need to be modified as they age?

In this discussion, Dr. Bove and Dr. Weinstock-Guttman will review:

• The effects that aging may have on patients with MS
• The interplay between menopause and MS
• How aging may affect the approach to disease management

EMD Serono is a business of Merck KGaA, Darmstadt, Germany.
©EMD Serono, Inc. All rights reserved. US/NPR/1019/0520B